Publication | Open Access

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Metastatic Breast CancerBreast OncologyMedicineAmg 386Weekly PaclitaxelBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular Oncology